ImmunoMet Therapeutics, Inc.

Targeting Metabolic Reprogramming in Fibrosis and Oncology

Add To Watchlist
General Information
Company Name
ImmunoMet Therapeutics, Inc.
Founded Year
2015
Location (Offices)
+1
Founders / Decision Makers
Edward Garmey - Consultant CMO Sungwuk Kim - CEO Revati Shreeniwas - Chief Medical Officer
Number of Employees
7
Industries
Biopharma, Biotechnology, Health Care +2
Funding Stage
Series B
Social Media

ImmunoMet Therapeutics, Inc. - Company Profile

ImmunoMet Therapeutics, Inc. is a clinical stage biotech company focused on targeting cellular metabolism to develop novel anti-fibrotic and anti-tumor therapies. The company's lead molecule, IM156, is a protein complex 1 (PC1) inhibitor that targets the Oxidative Phosphorylation (OXPHOS) pathway in mitochondria, reducing aberrant cell growth in fibrosis and select cancer cells. Notably, IM156 has successfully completed Phase 1 with good tolerability. In the realm of fibrosis, ImmunoMet is currently conducting a Phase 1 study in healthy volunteers and plans to progress into a Phase 2 PoC study in IPF patients in 4Q2021. Established in 2015, ImmunoMet is a spin-off from HanAll Biopharma, a Korean midsized public company. Post-spin-off, the company has raised $31 MM. The most recent investment of $7.00M came from a Venture Round at 08 February 2021, with participation from Mirae Asset Venture Investment, NHN Investment, GNTech VC, and SL Investment. ImmunoMet Therapeutics operates within the Biopharma, Biotechnology, Health Care, and Pharmaceutical industries.

Taxonomy: biotech, clinical stage, metabolic reprogramming, anti-fibrotic therapy, anti-tumor therapy, PC1 inhibitor, mitochondria, Phase 1 study, Phase 2 study, drug development, oncology products, cancer metabolism, immunometabolism, fibrosis research, oncology research

Funding Rounds & Investors of ImmunoMet Therapeutics, Inc. (3)

View All
Funding Stage Amount No. Investors Investors Date
Series B $7.00M 4
Mirae Asset Venture Investment, investor in ImmunoMet Therapeutics, Inc.'s Series B round NHN Investment, investor in ImmunoMet Therapeutics, Inc.'s Series B round SL Investment, investor in ImmunoMet Therapeutics, Inc.'s Series B round
G.N. Tech Venture 		08 Feb 2021
Series B $5.00M 6
Mirae Asset Venture Investment, investor in ImmunoMet Therapeutics, Inc.'s Series B round NHN Investment, investor in ImmunoMet Therapeutics, Inc.'s Series B round InterVest, investor in ImmunoMet Therapeutics, Inc.'s Series B round SL Investment, investor in ImmunoMet Therapeutics, Inc.'s Series B round
G.N. Tech Venture, Sungwuk Kim 		07 Mar 2017
Series A $5.20M - 08 Mar 2016

Latest News of ImmunoMet Therapeutics, Inc.

View All

No recent news or press coverage available for ImmunoMet Therapeutics, Inc..

Similar Companies to ImmunoMet Therapeutics, Inc.

View All
Pacylex Pharmaceuticals, Inc. - Similar company to ImmunoMet Therapeutics, Inc.
Pacylex Pharmaceuticals, Inc. A new target in cancer care - triggering selective lethality with a new class of drugs.
Isarna Therapeutics GmbH - Similar company to ImmunoMet Therapeutics, Inc.
Isarna Therapeutics GmbH Developing first in class antisense therapies for blockbuster retina indications.
Molecure - Similar company to ImmunoMet Therapeutics, Inc.
Molecure Fate can be altered.
Molecure - Similar company to ImmunoMet Therapeutics, Inc.
Molecure Fate can be altered.
Tarveda Therapeutics - Similar company to ImmunoMet Therapeutics, Inc.
Tarveda Therapeutics To discover, develop and commercialize a new class of potent and selective precision oncology medicines.
Circle Decoration Circle Decoration

Want to dive deeper into ImmunoMet Therapeutics, Inc.? Join now to access exclusive insights and find similar companies like this — powered by AI analytics.

Register Now